Geneos Wealth Management’s Lifecore Biomedical LFCR Stock Holding History

Geneos Wealth Management’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-675	Closed	-$7K	–	2873
2021 Q2	$7K	Hold	675	–	–	﹤0.01%	2339
2021 Q1	$7K	Hold	675	–	–	﹤0.01%	2536
2020 Q4	$7K	Hold	675	–	–	﹤0.01%	2367
2020 Q3	$6K	Hold	675	–	–	﹤0.01%	2124
2020 Q2	$6K	Hold	675	–	–	﹤0.01%	2089
2020 Q1	$5K	Hold	675	–	–	﹤0.01%	2039
2019 Q4	$7K	Hold	675	–	–	﹤0.01%	2102
2019 Q3	$7K	Hold	675	–	–	﹤0.01%	2006
2019 Q2	$6K	Hold	675	–	–	﹤0.01%	2074
2019 Q1	$8K	Hold	675	–	–	﹤0.01%	1907
2018 Q4	$7K	Hold	675	–	–	﹤0.01%	1886
2018 Q3	$9K	Hold	675	–	–	﹤0.01%	1881
2018 Q2	$10K	Hold	675	–	–	﹤0.01%	1722
2018 Q1	$8K	Hold	675	–	–	﹤0.01%	1724
2017 Q4	$8K	Hold	675	–	–	﹤0.01%	1705
2017 Q3	$8K	Hold	675	–	–	﹤0.01%	1641
2017 Q2	$10K	Hold	675	–	–	﹤0.01%	1538
2017 Q1	$8K	Hold	675	–	–	﹤0.01%	1556
2016 Q4	$9K	Hold	675	–	–	﹤0.01%	1465
2016 Q3	$9K	Hold	675	–	–	﹤0.01%	1398
2016 Q2	$7K	Hold	675	–	–	﹤0.01%	1430
2016 Q1	$7K	Buy	+675	New	+$7.41K	﹤0.01%	1415

Other funds holding LFCR

Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return

LPAM

Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CSC

Cove Street Capital El Segundo, California $76.6M AUM 36% 1-Year Est. Return

ICM

ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Geneos Wealth Management's LFCR Position: Q3 2021 in Review

Geneos Wealth Management sold out of Lifecore Biomedical (LFCR) in Q3 2021, closing a stake of 675 shares — an estimated $7K sold.

Geneos Wealth Management first reported a position in LFCR in Q1 2016 and held it in 22 quarters. The position peaked at $10K in Q2 2018. 92 funds tracked by Wall St. Rank hold LFCR as of Q3 2021.

Geneos Wealth Management reported no remaining Lifecore Biomedical position as of Q3 2021 after selling out during the quarter.
Geneos Wealth Management sold 675 Lifecore Biomedical shares in Q3 2021, an estimated $7K.
Geneos Wealth Management first reported a position in Lifecore Biomedical in Q1 2016 and held it in 22 quarters.
Geneos Wealth Management's Lifecore Biomedical position peaked at $10K in Q2 2018.
92 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q3 2021.

Based on Geneos Wealth Management's 13F filing for Q3 2021, filed 9 Nov 2021.